Assessment of Plasma Cytokine Profile Changes in Bevacizumab-Treated Retinopathy of Prematurity Infants
Authors:
Open Access
- 1 April 2016
- journal article
- research article
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 57 (4) , 1649-1654
Abstract
Purpose: We compared changes of plasma angiogenesis cytokine profiles in infants who were treated with intravitreal injection of bevacizumab (IVB) for type 1 retinopathy of prematurity (ROP) with age-matched preterm non-ROP infants. Methods: Thirteen infants with type 1 ROP and 13 age-matched preterm non-ROP infants were included. Blood samples were collected prior to treatment (time 0) and 6 weeks after the treatment (time 42). Plasma levels of nine cytokines from the angiogenesis growth factor panel and seven soluble cytokine receptors were measured using a magnetic multiplex assay. Results: Plasma cytokine profiles changed from time 0 to time 42 in both groups. In bevacizumab-treated ROP infants, the following plasma angiogenesis growth factor and soluble cytokine receptor levels decreased significantly: soluble VEGF-A (sVEGF-A; P = 0.0001), sVEGF-D (P = 0.04), angiopoietin-2 (Ang-2; P = 0.002), sVEGF receptor 1 (R1) and R2 (P = 0.005), soluble IL-6 receptor (sIL-6R; P = 0.002), soluble glycoprotein 130 (spg130; P = 0.0001), and soluble TNF receptor (sTNFR) I and II (P = 0.0001). The following factors and receptors increased significantly: sVEGF-C (P = 0.05), placental growth factor (PlGF; P = 0.02), endothelin-1 (ET-1; P = 0.0001), and FGF-1 (P = 0.02). At time 42, sVEGF-A, sgp130, sIL-6R, sTNFR I, and sTNFR II were lower, and ET-1 level was higher, in bevacizumab-treated ROP infants compared to age-matched non-ROP infants. Conclusions: The results suggest that bevacizumab treatment resulted in significant angiogenic cytokine profile changes in infants with severe ROP. The long-term clinical impact of these changes should be studied carefully.Keywords
This publication has 23 references indexed in Scilit:
- Pharmacokinetics of Bevacizumab and Its Effects on Serum VEGF and IGF-1 in Infants With Retinopathy of PrematurityInvestigative Ophthalmology & Visual Science, 2015
- The Relationship Between Cord Blood Cytokine Levels and Perinatal Factors and Retinopathy of Prematurity: A Gestational Age-Matched Case-Control StudyInvestigative Ophthalmology & Visual Science, 2013
- An update on progress and the changing epidemiology of causes of childhood blindness worldwideJournal of American Association for Pediatric Ophthalmology and Strabismus, 2012
- VEGF signalling controls GnRH neuron survival via NRP1 independently of KDR and blood vesselsDevelopment, 2011
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityNew England Journal of Medicine, 2011
- Perinatal Systemic Inflammatory Response Syndrome and Retinopathy of PrematurityPediatric Research, 2010
- Intravitreous Bevacizumab as Anti–Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity: A Morphologic StudyArchives of Ophthalmology (1950), 2008
- Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot studyBritish Journal of Ophthalmology, 2008
- Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurityGraefe's Archive for Clinical and Experimental Ophthalmology, 2007
- Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-AnalysisAmerican Journal of Kidney Diseases, 2007